Omeprazole vs Pantoprazole

## Overview

Pantoprazole is often considered the preferred PPI for patients on clopidogrel or other antiplatelet therapy because it has the weakest CYP2C19 inhibitory activity among PPIs. This makes it less likely to impair clopidogrel's bioactivation.

## Mechanism of Action

Both irreversibly inhibit H+/K+-ATPase in the parietal cell. Pantoprazole binds to Cys813 and Cys822 of the proton pump (omeprazole binds Cys813 and Cys892), a subtle but potentially relevant difference in binding site.

## Pharmacokinetics

Pantoprazole: CYP2C19 (primary) + CYP3A4, but pantoprazole produces less potent CYP2C19 inhibition and has fewer drug interactions overall. Half-life ~1 h. Pantoprazole is available in both oral and IV formulations, making it commonly used in the ICU setting.

## Drug Interactions

Pantoprazole has the cleanest drug interaction profile among PPIs due to minimal CYP2C19 inhibitory effect. Multiple guidelines recommend pantoprazole as the preferred PPI in patients requiring concurrent clopidogrel therapy.

## Clinical Evidence

Equivalent efficacy to omeprazole for GERD, PUD, and H. pylori eradication. The IV formulation of pantoprazole is widely used for upper GI bleeding management (reducing high-dose PPI infusion).

## Key Takeaways

- Pantoprazole: preferred PPI with clopidogrel (least CYP2C19 inhibition)
- Pantoprazole: IV formulation available (ICU, upper GI bleed)
- Both equally effective for standard acid suppression indications